Top Markets
Coin of the day
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
株式のランク #29359
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
株価
$0.365
最終同期: 2025-08-01
時価総額
$21.54M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Elevation Oncology, Inc. (ELEV)

カテゴリー

Elevation Oncology, Inc.(ELEV)の配当利回りの履歴
Elevation Oncology, Inc.(銘柄コード: ELEV)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Elevation Oncology, Inc.(ELEV)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)